...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: AACR 2018

"....Perhaps it is time to seriously consider the recombination of RVX and Zenith and pool all talent and financial resources...."

No thanks.  Looks like a positive for RVX and a negative for ZEN to me.

Share
New Message
Please login to post a reply